Trifluridine/Tipiracil (TAS-102) in refractory metastatic colorectal cancer: Real-world data of 13 oncological centers in Portugal

被引：0

作者：

Tomas, T. ^{[1
]}

Nogueira-Costa, G. ^{[2
]}

Eriz, I. ^{[1
]}

Vitorino, M. ^{[3
]}

Baptista, M. Vaz ^{[4
]}

Correia, M. ^{[5
]}

Pereira, T. ^{[6
]}

Oliveira, A. ^{[7
]}

Leal da Costa, L. ^{[8
]}

Pimenta, J. ^{[9
]}

Liu, P. ^{[9
]}

Peixeto, I. ^{[10
]}

Luz, P. ^{[11
]}

Gil, L. ^{[12
]}

Silva, D. ^{[12
]}

Caleca, T. ^{[12
]}

Neves, M. ^{[13
]}

Quintela, A. ^{[14
]}

Monteiro, A. ^{[15
]}

Atalaia, G. ^{[1
]}

Silva, M. ^{[16
]}

Fiuza, T. ^{[16
]}

机构：

[1] Hosp Prof Doutor Fernando da Fonseca, Lisbon, Portugal

[2] Ctr Hosp Barreiro Montijo, Barreiro, Portugal

[3] Hosp Prof Dr Fernando Fonseca, Amadora, Portugal

[4] Hosp Prof Doutor Fernando Fonseca, Lisbon, Portugal

[5] EPE, Hosp Distrital Santarem, Santarem, Portugal

[6] EPE, Inst Portugues Oncol Coimbra Francisco Gentil, Coimbra, Portugal

[7] Hosp Espirito Santo Evora, Evora, Portugal

[8] Hosp Beatriz Angelo, Loures, Portugal

[9] Ctr Hosp Tras Os Montes & Alto Douro, Vila Real, Portugal

[10] EPE, Hosp Geral Santo Antonio, Porto, Portugal

[11] Ctr Hosp Univ Algarve, EPE, Faro, Portugal

[12] EPE, Ctr Hosp Setubal, Setubal, Portugal

[13] Ctr Hosp Lisboa Ocidental, Hosp Sao Francisco Xavier, Lisbon, Portugal

[14] Hosp CUF Descobertas, Lisbon, Portugal

[15] Hosp Vila Franca De Xira, Vila Franca De Xira, Portugal

[16] EPE, Hosp Prof Dr Fernando Fonseca, Amadora, Portugal

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P - 320

引用

页码：88 / 88

页数：1

共 50 条

[31] Randomized study evaluating trifluridine/tipiracil (TAS-102) versus + trifluridine/tipiracil plus bevacizumab as last-line therapy in patients with chemorefractory unresectable metastatic colorectal cancer (mCRC).
Pfeiffer, Per
Yilmaz, Mette
Moller, Soren
Maltha, Line
Krogh, Merete
Zitnjak, Daniela
Szameitat, Caroline Lemb
Hejlesen, Finn
Thomsen, Karina Gravgaard
Qvortrup, Camilla
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[32] TAS-102 for the treatment of metastatic colorectal cancer
Salvatore, Lisa
Rossini, Daniele
Moretto, Roberto
Cremolini, Chiara
Schirripa, Marta
Antoniotti, Carlotta
Marmorino, Federica
Loupakis, Fotios
Falcone, Alfredo
Masi, Gianluca
EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (11) : 1283 - 1292
[33] Safety and Efficacy of Trifluridine-Tipiracil Hydrochloride Oral Combination (TAS-102) in Patients with Unresectable Colorectal Cancer
Narihiro, Satoshi
Suwa, Katsuhito
Ushigome, Takuro
Ohtsu, Masamichi
Ryu, Syunjin
Shimoyama, Yuya
Okamoto, Tomoyoshi
Yanaga, Katsuhiko
IN VIVO, 2018, 32 (06): : 1643 - 1646
[34] Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer
Gianluca Arrichiello
Alessandra Perrone
Stefania Napolitano
Giulia Martini
Vincenzo De Falco
Pasquale Incoronato
Maria Maddalena Laterza
Gaetano Facchini
Vincenzo Famiglietti
Valeria Nacca
Fernando Paragliola
Rossella Napolitano
Gabriella Suarato
Antonella Nicastro
Erika Martinelli
Davide Ciardiello
Fortunato Ciardiello
Teresa Troiani
Targeted Oncology, 2022, 17 : 635 - 642
[35] Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study"
Coutzac, Clelia
Trouilloud, Isabelle
Pascal, Artru
Henriques, Julie
Masson, Therese
Doat, Solene
Bouche, Olivier
Coriat, Romain
Saint, Angelique
Moulin, Valerie
Vernerey, Dewi
Gallois, Claire
De La Fouchardiere, Christelle
Tougeron, David
Taieb, Julien
CLINICAL COLORECTAL CANCER, 2022, 21 (02) : 132 - 140
[36] Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer
Arrichiello, Gianluca
Perrone, Alessandra
Napolitano, Stefania
Martini, Giulia
De Falco, Vincenzo
Incoronato, Pasquale
Laterza, Maria Maddalena
Facchini, Gaetano
Famiglietti, Vincenzo
Nacca, Valeria
Paragliola, Fernando
Napolitano, Rossella
Suarato, Gabriella
Nicastro, Antonella
Martinelli, Erika
Ciardiello, Davide
Ciardiello, Fortunato
Troiani, Teresa
TARGETED ONCOLOGY, 2022, 17 (06) : 635 - 642
[37] Real-world efficacy and safety of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies
Martinez Lago, N.
Alonso de Castro, B.
Varela Ponte, R.
Reboredo Rendo, C.
Gomez-Randulfe Rodriguez, M.
Grana Suarez, B.
de la Camara Gomez, J.
Mateos Salvador, M.
Busto Fernandez, F.
Calleja Chucla, T.
Reboredo-Lopez, M.
ANNALS OF ONCOLOGY, 2021, 32 : S106 - S107
[38] Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil
Cheung, W. Y.
Kavan, P.
Dolley, A.
CURRENT ONCOLOGY, 2020, 27 (05) : E451 - E458
[39] Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
Patel, Anuj K.
Barghout, Victoria
Yenikomshian, Mihran A.
Germain, Guillaume
Jacques, Philippe
Laliberte, Francois
Duh, Mei S.
ONCOLOGIST, 2020, 25 (01): : E75 - E84
[40] Sidedness of the primary tumor on the effect of TAS-102 for refractory metastatic colorectal cancer
Ueda, S.
Tsuboguchi, Y.
Nakatani, Y.
Tsuya, A.
Nishina, S-I.
Akiyoshi, K.
Okazaki, S.
Tokunaga, S.
Daga, H.
ANNALS OF ONCOLOGY, 2018, 29

← 1 2 3 4 5 →